CV Sciences, Inc. Appoints Dr. Stephen M. Schmitz to its Board of Directors

LAS VEGAS, NV–(Marketwired – May 16, 2017) – CV Sciences, Inc. (OTCQB: CVSI) (“CV Sciences”, “our” or “we”), today announced the appointment of Stephen M. Schmitz, MD, MPH to its Board of Directors effective May 10, 2017.

CV Sciences’ President and CEO Michael J. Mona, Jr. commented, “We are very pleased to have Dr. Schmitz join our Board and look forward to his contributions. His extensive medical background and proven track record in the pharmaceutical industry, including his safety and regulatory expertise, will be invaluable to us as we move our drug development program forward to commercialization.”

Dr. Schmitz is a board certified physician with nearly 20 years of experience in the pharmaceutical industry with extensive experience in drug safety, dietary supplement safety, clinical development and regulatory affairs. He has worked for several major pharmaceutical companies in the therapeutic areas of neurosciences, ophthalmology, medical devices and orphan (rare) diseases. While the focus of his pharma career has been in drug safety, he has also worked in clinical development and served as the medical monitor for numerous studies. Before entering the pharmaceutical industry, Dr. Schmitz worked in preventive medicine and practiced family and occupational medicine. Dr. Schmitz earned his B.S. in biology from Fairfield University, an M.D. from Rutgers New Jersey Medical School, and his M.P.H. from the Boston University School of Public Health.

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from or by visiting


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

Robert Haag
Managing Director
IRTH Communications
[email protected]